KUALA LUMPUR, Nov 14 (Bernama) -- Amsterdam-based pioneering innovator in the field of advanced wound care, DEBx Medical announced the successful completion of its second capital investment round led by TVM Capital Healthcare.
According to DEBx Medical in a statement, the funding will accelerate the company’s global expansion into major markets around the world.
“This round of funding will allow us to enter key markets around the world, where the burden of chronic wounds remains significant. Our investors’ support is a strong validation of our product’s potential to transform wound care practices worldwide,” said DEBx Medical chief executive officer, Bert Quint.
The investment follows a successful initial round of funding and reflects growing confidence in DEBx Medical’s innovative approach to chronic wound management, specifically through its breakthrough solution, DEBRICHEM, a topical desiccating agent used to eradicate biofilm and infection from chronic wounds.
This second investment round will support the company’s strategy to expand into highly regulated and competitive markets, further supporting DEBx Medical’s mission to transform the management of chronic wounds and improve patient outcomes.
Chronic wounds impose a considerable burden on healthcare systems worldwide, not just due to their prevalence but also due to the associated costs, complications, and impacts on patients' quality of life.
DEBRICHEM offers an unparalleled solution for completely eradicating biofilm and infection from chronic wounds, and with CE and ISO certifications obtained, the company has successfully treated thousands of patients since its market introduction.
This solution has already made a significant impact in Europe and parts of the Middle East and North Africa (MENA) region, including Saudi Arabia, offering healthcare professionals a powerful solution to treat chronic wounds.
In addition to expanding its geographic reach, DEBx Medical plans to continue advancing its research and development efforts to introduce new solutions in wound care.
The company’s focus on clinical data and evidence-based medicine will remain a driving force as it seeks to broaden its product portfolio and address unmet needs in chronic wound treatment.
-- BERNAMA
